Literature DB >> 16543488

Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro.

Sangmi Chung1, Byoung-Soo Shin, Michelle Hwang, Thomas Lardaro, Un Jung Kang, Ole Isacson, Kwang-Soo Kim.   

Abstract

Neural precursors (NPs) derived from ventral mesencephalon (VM) normally generate dopaminergic (DA) neurons in vivo but lose their potential to differentiate into DA neurons during mitogenic expansion in vitro, hampering their efficient use as a transplantable and experimental cell source. Because embryonic stem (ES) cell-derived NPs (ES NP) do not go through the same maturation process during in vitro expansion, we hypothesized that expanded ES NPs may maintain their potential to differentiate into DA neurons. To address this, we expanded NPs derived from mouse embryonic day-12.5 (E12.5) VM or ES cells and compared their developmental properties. Interestingly, expanded ES NPs fully sustain their ability to differentiate to the neuronal as well as to the DA fate. In sharp contrast, VM NPs almost completely lost their ability to become neurons and tyrosine hydroxylase-positive (TH(+)) neurons after expansion. Expanded ES NP-derived TH(+) neurons coexpressed additional DA markers such as dopa decarboxylase and DAT (dopamine transporter). Furthermore, they also expressed other midbrain DA markers, including Nurr1 and Pitx3, and released significant amounts of DA. We also found that these ES NPs can be cryopreserved without losing their proliferative and developmental potential. Finally, we tested the in vivo characteristics of the expanded NPs derived from J1 ES cells with low passage number. When transplanted into the mouse striatum, the expanded NPs as well as control NPs efficiently generated DA neurons expressing mature DA markers, with approximately 10% tumor formation in both cases. We conclude that ES NPs maintain their developmental potential during in vitro expansion, whereas mouse E12.5 VM NPs do not.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543488      PMCID: PMC2613224          DOI: 10.1634/stemcells.2005-0558

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  29 in total

1.  Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity.

Authors:  H Kawasaki; K Mizuseki; S Nishikawa; S Kaneko; Y Kuwana; S Nakanishi; S I Nishikawa; Y Sasai
Journal:  Neuron       Date:  2000-10       Impact factor: 17.173

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells.

Authors:  A Storch; G Paul; M Csete; B O Boehm; P M Carvey; A Kupsch; J Schwarz
Journal:  Exp Neurol       Date:  2001-08       Impact factor: 5.330

4.  Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro.

Authors:  S Okabe; K Forsberg-Nilsson; A C Spiro; M Segal; R D McKay
Journal:  Mech Dev       Date:  1996-09       Impact factor: 1.882

5.  In vitro differentiation of transplantable neural precursors from human embryonic stem cells.

Authors:  S C Zhang; M Wernig; I D Duncan; O Brüstle; J A Thomson
Journal:  Nat Biotechnol       Date:  2001-12       Impact factor: 54.908

6.  Ascorbic acid increases the yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors.

Authors:  J Yan; L Studer; R D McKay
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

7.  Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen.

Authors:  L Studer; M Csete; S H Lee; N Kabbani; J Walikonis; B Wold; R McKay
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

8.  Timing of CNS cell generation: a programmed sequence of neuron and glial cell production from isolated murine cortical stem cells.

Authors:  X Qian; Q Shen; S K Goderie; W He; A Capela; A A Davis; S Temple
Journal:  Neuron       Date:  2000-10       Impact factor: 17.173

9.  Primitive neural stem cells from the mammalian epiblast differentiate to definitive neural stem cells under the control of Notch signaling.

Authors:  Seiji Hitoshi; Raewyn M Seaberg; Cheryl Koscik; Tania Alexson; Susumu Kusunoki; Ichiro Kanazawa; Shoji Tsuji; Derek van der Kooy
Journal:  Genes Dev       Date:  2004-08-01       Impact factor: 11.361

10.  Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C.

Authors:  Emmanuel Garcion; Aida Halilagic; Andreas Faissner; Charles ffrench-Constant
Journal:  Development       Date:  2004-07       Impact factor: 6.868

View more
  22 in total

1.  A protocol for the differentiation of human embryonic stem cells into dopaminergic neurons using only chemically defined human additives: Studies in vitro and in vivo.

Authors:  Lorraine Iacovitti; Angela E Donaldson; Cheryl E Marshall; Sokreine Suon; Ming Yang
Journal:  Brain Res       Date:  2006-11-21       Impact factor: 3.252

Review 2.  Strengths and limitations of the neurosphere culture system.

Authors:  Josephine B Jensen; Malin Parmar
Journal:  Mol Neurobiol       Date:  2006-12       Impact factor: 5.590

3.  Laser-assisted photoablation of human pluripotent stem cells from differentiating cultures.

Authors:  Stefanie Terstegge; Franziska Winter; Barbara H Rath; Iris Laufenberg; Claudia Schwarz; Anke Leinhaas; Florian Levold; Andreas Dolf; Simone Haupt; Philipp Koch; Elmar Endl; Oliver Brüstle
Journal:  Stem Cell Rev Rep       Date:  2010-06       Impact factor: 5.739

4.  Nucleotides affect neurogenesis and dopaminergic differentiation of mouse fetal midbrain-derived neural precursor cells.

Authors:  Jasmin Delic; Herbert Zimmermann
Journal:  Purinergic Signal       Date:  2011-01-06       Impact factor: 3.765

5.  Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease.

Authors:  Yong-Hee Rhee; Ji-Yun Ko; Mi-Yoon Chang; Sang-Hoon Yi; Dohoon Kim; Chun-Hyung Kim; Jae-Won Shim; A-Young Jo; Byung-Woo Kim; Hyunsu Lee; Suk-Ho Lee; Wonhee Suh; Chang-Hwan Park; Hyun-Chul Koh; Yong-Sung Lee; Robert Lanza; Kwang-Soo Kim; Sang-Hun Lee
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

Review 6.  Three-Dimensional Models of the Human Brain Development and Diseases.

Authors:  Mehdi Jorfi; Carla D'Avanzo; Doo Yeon Kim; Daniel Irimia
Journal:  Adv Healthc Mater       Date:  2017-08-28       Impact factor: 9.933

7.  Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse.

Authors:  Jisook Moon; Hyun-Seob Lee; Jun Mo Kang; Junpil Park; Amanda Leung; Sunghoi Hong; Sangmi Chung; Kwang-Soo Kim
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

8.  Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.

Authors:  Igor Nasonkin; Vasiliki Mahairaki; Leyan Xu; Glen Hatfield; Brian J Cummings; Charles Eberhart; David K Ryugo; Dragan Maric; Eli Bar; Vassilis E Koliatsos
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

9.  Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons.

Authors:  Sunghoi Hong; Un Jung Kang; Ole Isacson; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2007-10-18       Impact factor: 5.372

Review 10.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.